Nonrecurring Expenses Fund
Schedules
TAFS: 075-0125 /X - Nonrecurring Expenses Fund
| Line # | Split | Description | Iteration 2 Previously Approved Amount | Iteration 3 OMB Action Amount | Footnotes |
|---|---|---|---|---|---|
| 1000 | DE2 | Discretionary Estimated - Unob Bal: Brought forward from 75-75-X-0125.006 (FDA), Oct | $41,246,251 | -$41,246,251 $0 | |
| 1000 | DE3 | Discretionary Estimated - Unob Bal: Brought forward from 75-75-X-0125.008 (NIH), Oct 1 | $10,836,407 | -$10,836,407 $0 | |
| 1000 | DE4 | Discretionary Estimated - Unob Bal: Brought forward from 75-75-X-0125.009 (CDC), October 1 | $209,134,891 | -$209,134,891 $0 | |
| 1000 | DE6 | Discretionary Estimated - Unob Bal: Brought forward from 75-X-0125, October 1 | $630,727,792 | -$630,727,792 $0 | |
| 1000 | DE1 | Discretionary Estimated- Unob Bal: Brought forward from 75-75-X-0125.005 (CMS), October 1 | $3,330,140 | -$3,330,140 $0 | |
| 1000 | DE5 | Discretionary Estimated - Unob Bal: Brought forward from 75-75-X-0125.010 (IHS), Oct 1 | $338,742,693 | -$338,742,693 $0 | |
| 1000 | DA2 | Discretionary Actual - Unob Bal: Brought forward from 75-75-X-0125.006 (FDA), Oct | Line added— | +$41,245,211 $41,245,211 | |
| 1000 | DA3 | Discretionary Actual - Unob Bal: Brought forward from 75-75-X-0125.008 (NIH), Oct 1 | Line added— | +$4,499,319 $4,499,319 | |
| 1000 | DA4 | Discretionary Actual - Unob Bal: Brought forward from 75-75-X-0125.009 (CDC), October 1 | Line added— | +$204,139,024 $204,139,024 | |
| 1000 | DA6 | Discretionary Actual - Unob Bal: Brought forward from 75-X-0125, October 1 | Line added— | +$782,497,662 $782,497,662 | |
| 1000 | DA1 | Discretionary Actual- Unob Bal: Brought forward from 75-75-X-0125.005 (CMS), October 1 | Line added— | +$3,333,885 $3,333,885 | |
| 1000 | DA5 | Discretionary Actual- Unob Bal: Brought forward from 75-75-X-0125.010 (IHS), Oct 1 | Line added— | +$324,965,661 $324,965,661 | |
| 1010 | 1 | Unob Bal: antic nonexpenditure transfers from 75-X-0125 | Line added— | -$321,998,000 -$321,998,000 | |
| 1011 | 1 | Unob Bal: Antic Transferred to other accounts 75-75-X-0125.006 (FDA) | Line added— | +$109,070,000 $109,070,000 | |
| 1011 | 2 | Unob Bal: Antic Transferred to other accounts 75-75-X-0125.008 (NIH) | Line added— | +$63,140,000 $63,140,000 | |
| 1011 | 3 | Unob Bal: Antic Transferred to other accounts 75-75-X-0125.009 (CDC) | Line added— | +$35,000,000 $35,000,000 | |
| 1011 | 4 | Unob Bal: Antic Transferred to other accounts 75-75-X-0125.010 (IHS) | Line added— | +$114,788,000 $114,788,000 | |
| 1012 | Estimated- Unob Bal: Transfers betw expired\unexpired accts | Line added— | +$1,002,000,000 $1,002,000,000 | ||
| 1021 | Unob Bal: Recov of prior year unpaid obligations | Line added— | +$236,117 $236,117 | ||
| 1061 | 1 | Unob Bal: Antic Recov of prior year unpaid obligations 75-X-0125 | $5,000,000 | $5,000,000 | |
| 1920 | Total budgetary resources avail (disc. and mand.) | $1,239,018,174 | +$1,128,898,705 $2,367,916,879 | ||
| 6018 | Nonrecurring Expenses Fund Projects | $1,043,015,846 | +$653,239,103 $1,696,254,949 | ||
| 6019 | NIH B&F | $1,137,451 | -$197,064 $940,387 | ||
| 6020 | CDC Chamblee Campus | $17,692,000 | -$4,718,992 $12,973,008 | ||
| 6170 | 1 | Apportioned in FY 2024 and future fiscal years - Nonrecurring Expenses Fund Projects | $177,172,877 | +$480,575,658 $657,748,535 | |
| 6190 | Total budgetary resources available | $1,239,018,174 | +$1,128,898,705 $2,367,916,879 | See footnotes below | |
| Footnotes for line 6190 (Previous): | A1: Not reflected on this reapportionment is $650,000,000, which is precluded from obligation during the short-term CR period as automatically apportioned via Attachment B of OMB Bulletin 22-02. [Rationale: Footnote signifies that this TAFS has received or may receive an automatic apportionment.] | ||||
| Footnotes for line 6190 (Current): | A1: Not reflected on this reapportionment is $650,000,000, which is precluded from obligation during the short-term CR period as automatically apportioned via Attachment B of OMB Bulletin 22-02. [Rationale: Footnote signifies that this TAFS has received or may receive an automatic apportionment.] | ||||
Footnotes
Footnotes provide further information about, or establish further legal requirements related to the use of, the funds in a given line or set of lines in an apportionment. If footnotes appear on lines 1920 or 6190, they apply to all the lines in the 1xxx and 6xxx sections, respectively. The following are all the footnotes associated with this file.
| Number | Text |
|---|---|
| A1 | Not reflected on this reapportionment is $650,000,000, which is precluded from obligation during the short-term CR period as automatically apportioned via Attachment B of OMB Bulletin 22-02. [Rationale: Footnote signifies that this TAFS has received or may receive an automatic apportionment.] |
The following are all of the footnotes associated with the previous iteration of this file. Note that previous iterations of accounts in this file may come from multiple previous files.
| Number | Text |
|---|---|
| A1 | Not reflected on this reapportionment is $650,000,000, which is precluded from obligation during the short-term CR period as automatically apportioned via Attachment B of OMB Bulletin 22-02. [Rationale: Footnote signifies that this TAFS has received or may receive an automatic apportionment.] |
Notes about this page
- † Links to public laws are automatically generated and are not guaranteed to be accurate.